How to Successfully Market Allogeneic Therapies

Dan Schroen, head of Photo 51, a Fingerpaint company and consultancy focused solely on advanced therapeutics, shared with Pharmaceutical Executive magazine 3 approaches biopharma can use right now to market allogeneic therapies from clinical trials to market access.

In his article, Schroen outlines what allogeneic therapies mean to patients and the future of medicine and what needs to be done to make sure patients have access to them.

Read his insights in Pharmaceutical Executive and connect with Schroen on LinkedIn.